Overview
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4).
Lenvanib
- Generic Name
- Lenvatinib
- Therapeutic Area
- Oncology
- Dosage Form
- Capsules
- Strength
- 4 mg & 10 mg
- Pack Size
- 10's, 20's & 30's
- Registration Number
- 130717 & 130718
Indication
Treating Advanced cancers, including thyroid cancer(that doesn’t respond to radioactive iodine), liver cancer(hepatocellular carcinoma), kidney cancer (renal cell carcinoma), and endometrial cancer.
